mail
versión imprimible
 
 

12th Alzheimer's and Parkinson's Drug Development Summit

Evvnt Promotion / evvnt
Archivo
-
23.04.2024 - 25.04.2024  Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
 
Temas de la conferencia
After a 17-year hiatus in drug approvals for neurodegeneration, disease-modifying drugs for AD have finally broken the ice. With Lecanemab's clinically proven 30% reduction in cognitive decline receiving the green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their heels for approval, 58 new trials entering the pipeline this year, and the alpha-synuclein self-seeding assay changing the game for PD drug development.
Organizador profesional (PCO)
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/2146026-3?pid=4832

Speakers: Achim Kless, PhD, Senior Director Pain Genetics, Eli Lilly and Co., Arnon Rosenthal, Co-Founder and Chief Executive Officer, Alector Pharmaceuticals LLC, and more
 

Información e inscripción:

https://go.evvnt.com/2146026-2?pid=4832
Ms. Erin Thomas
 
Categorías
Medicina General
Idioma
Inglés
Cuota del Congreso
USD 2999.00 - USD 5197.00
Los participantes esperaban
1000 - 1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."

Center of ExcellenceSwiss Tropical and Public Health InstituteÖsterreichisches Rotes KreuzHilfswerk AustriaÄrztekammer für WienHelix - Forschung & Beratung WienAnästhesie in Entwicklungsländern e. V.newTree